Sameh Tawfik

Array ( [id] => 11205327 [patent_doc_number] => 09434947 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-09-06 [patent_title] => 'Modulation of KCNH2 isoform expression by oligonucleotides as a therapeutic approach for long QT syndrome' [patent_app_type] => utility [patent_app_number] => 14/600958 [patent_app_country] => US [patent_app_date] => 2015-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 18 [patent_no_of_words] => 9844 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14600958 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11815143 [patent_doc_number] => 09719086 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-01 [patent_title] => 'Micro-RNA family that modulates fibrosis and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/592686 [patent_app_country] => US [patent_app_date] => 2015-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 28 [patent_no_of_words] => 30912 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14592686 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11815144 [patent_doc_number] => 09719087 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-01 [patent_title] => 'Micro-RNA family that modulates fibrosis and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/592699 [patent_app_country] => US [patent_app_date] => 2015-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 28 [patent_no_of_words] => 30917 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14592699 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11815145 [patent_doc_number] => 09719088 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-01 [patent_title] => 'Micro-RNA family that modulates fibrosis and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/592737 [patent_app_country] => US [patent_app_date] => 2015-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 28 [patent_no_of_words] => 30919 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14592737 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12347619 [patent_doc_number] => 09951376 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-24 [patent_title] => Methods for the selection of aptamers [patent_app_type] => utility [patent_app_number] => 14/590634 [patent_app_country] => US [patent_app_date] => 2015-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 8 [patent_no_of_words] => 9825 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 317 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14590634 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11915630 [patent_doc_number] => 09783808 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-10-10 [patent_title] => 'Ovarian cancer-specific aptamers and applications thereof' [patent_app_type] => utility [patent_app_number] => 14/558659 [patent_app_country] => US [patent_app_date] => 2014-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 21 [patent_no_of_words] => 6687 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 183 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14558659 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11212192 [patent_doc_number] => 09441221 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-09-13 [patent_title] => 'Compositions and methods for gene silencing' [patent_app_type] => utility [patent_app_number] => 14/529923 [patent_app_country] => US [patent_app_date] => 2014-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 59 [patent_figures_cnt] => 97 [patent_no_of_words] => 39304 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14529923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10318868 [patent_doc_number] => 20150203870 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-23 [patent_title] => 'METHODS AND COMPOSITIONS RELATING TO IMPROVED LENTIVIRAL VECTOR PRODUCTION SYSTEMS' [patent_app_type] => utility [patent_app_number] => 14/525520 [patent_app_country] => US [patent_app_date] => 2014-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 25095 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14525520 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9895148 [patent_doc_number] => 20150050347 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-19 [patent_title] => 'REVERSE MICELLE SYSTEM COMPRISING NUCLEIC ACIDS AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/520399 [patent_app_country] => US [patent_app_date] => 2014-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 12428 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14520399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15883307 [patent_doc_number] => 10647986 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-12 [patent_title] => Dynamin 2 inhibitor for the treatment of centronuclear myopathies [patent_app_type] => utility [patent_app_number] => 15/030127 [patent_app_country] => US [patent_app_date] => 2014-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 30 [patent_no_of_words] => 15933 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15030127 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11054697 [patent_doc_number] => 20160251660 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-01 [patent_title] => 'NUCLEIC ACID APTAMER CAPABLE OF SPECIFICALLY BINDING TO TEBUCONAZOLE, MEFENACET AND INABENFIDE, AND USE THEROF' [patent_app_type] => utility [patent_app_number] => 15/028931 [patent_app_country] => US [patent_app_date] => 2014-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 6615 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15028931 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13237431 [patent_doc_number] => 10131907 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-11-20 [patent_title] => Glycoconjugates of RNA interference agents [patent_app_type] => utility [patent_app_number] => 14/500356 [patent_app_country] => US [patent_app_date] => 2014-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 20532 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14500356 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11018338 [patent_doc_number] => 20160215291 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-28 [patent_title] => 'NUCLEIC ACIDS AND METHODS FOR THE TREATMENT OF POMPE DISEASE' [patent_app_type] => utility [patent_app_number] => 14/917118 [patent_app_country] => US [patent_app_date] => 2014-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 17519 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14917118 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10187738 [patent_doc_number] => 09217149 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-12-22 [patent_title] => 'Pharmaceutical composition for treating cancer' [patent_app_type] => utility [patent_app_number] => 14/476459 [patent_app_country] => US [patent_app_date] => 2014-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 14 [patent_no_of_words] => 7601 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14476459 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12145017 [patent_doc_number] => 09879260 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-30 [patent_title] => 'Micro-RNA regulation of bone loss' [patent_app_type] => utility [patent_app_number] => 14/913005 [patent_app_country] => US [patent_app_date] => 2014-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 27102 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14913005 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9919632 [patent_doc_number] => 20150074836 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-12 [patent_title] => 'MUTATIONS OF THE PARKIN GENE, COMPOSITIONS, METHODS AND USES' [patent_app_type] => utility [patent_app_number] => 14/454026 [patent_app_country] => US [patent_app_date] => 2014-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 14574 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14454026 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11410038 [patent_doc_number] => 09557339 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-31 [patent_title] => 'Nucleic acid molecule having binding affinity to rodent-derived IgG antibody, binder, detection reagent, and detection kit' [patent_app_type] => utility [patent_app_number] => 14/336723 [patent_app_country] => US [patent_app_date] => 2014-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 16 [patent_no_of_words] => 9055 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14336723 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10282006 [patent_doc_number] => 20150167003 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-18 [patent_title] => 'GENE VECTOR' [patent_app_type] => utility [patent_app_number] => 14/332222 [patent_app_country] => US [patent_app_date] => 2014-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 24232 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14332222 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15785379 [patent_doc_number] => 10626400 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-21 [patent_title] => Stabilised formulations of RNA [patent_app_type] => utility [patent_app_number] => 15/323599 [patent_app_country] => US [patent_app_date] => 2014-07-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 14403 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15323599 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10806816 [patent_doc_number] => 20160152974 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-02 [patent_title] => 'COMPOUNDS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION FOR IMPROVING A DIABETIC PROFILE' [patent_app_type] => utility [patent_app_number] => 14/900320 [patent_app_country] => US [patent_app_date] => 2014-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29484 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 18 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14900320 [rel_patent_id] =>[rel_patent_doc_number] =>)